FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure

Friends of Cancer Research proposes realignment of medical product functions by disease area without regard to modality; former commissioners give some support but new drugs Director Jenkins warns about unintended consequences that could negatively impact innovation and approvals.